Amethyst is the largest private provider of Radiation Oncology services in Europe treating over 29,000 patients a year. It operates some of the highest volume Linear Accelerators (Linacs) in Europe, with 220 patients a day treated in its high-volume centres; equivalent to +70 patients per Linac per day; bringing treatment times to eight minutes per treatment fraction. This is double the typical Linac utilisation to be found in most government operated Radiation Treatment Centres anywhere.

Amethyst was founded in 2010 to deliver next generation (non surgical) Oncology treatments to address the legacy demand and supply deficit (both quantitative and qualitative) across the international Cancer Care market. From its first greenfield Centre build in Bucharest in 2010, Amethyst has expanded across Austria, Poland and Romania, Italy, France and UK. Amethyst now operates 16 specialist Cancer Treatment Centres, comprising 25 Linear Accelerators (Linacs) and three Gamma Knife Radiosurgery treatment systems.

Amethyst was one of the first operators to deploy cutting edge radiation techniques such as Intensity Modulated Radiotherapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) and Image Guided Radiotherapy (IGRT) at a time when government systems across the world were typically using conformal radiation technology. These new techniques deliver more precisely targeted radiation treatment to patients with vastly improved outcomes sparing less damage to healthy tissues and organs at risk.

Amethyst strives to evolve and enhance its established leadership position in the delivery of radiation and oncology techniques with the recent move towards delivering Stereotactic Radiotherapy for precise irradiation of image defined lesions; using higher radiation doses delivered in smaller numbers of fractions to target the tumour more precisely. The technique spares the surrounding healthy normal tissues; lowering the risk of side effects and reducing the required number of treatments per patient episode.

Amethyst operates its Treatment Centres to the highest quality standards, underpinned with robust clinical governance and exceptional focus on patient experience and treatment outcomes. It achieves this by working in partnership with leading University Teaching Hospitals (including but not limited to):

• Institut Curie, France

• Institut Gustave Roussy, France

• Freiburg and Wurzburg Universitie, Germany

• UZ Brussel, Belgium

• University College London Hospital, UK

• Sheffield Teaching Hospitals NHS FT,UK

• The National Hospital for Neurology and Neurosurgery, Queen Square, UK

Amethyst’s Medical Board comprises some of the foremost expert Oncologists in the international field, providing strong clinical oversight and governance across the Group’s Centers.

Amethyst Medical Board comprises:

- Prof. Nick Plowman, Bart’s and the London University Teaching Hospitals

- Prof. Jean March Cosset, Marie Curie Institut, Paris, France

- Dr Christine Haie-Meder, Institut Gustav Roussy, Paris, France

- Professor Guy Storme, University Hospital Brussels/UZ Brussel, Belgium

- Professor Chiricuta, Wurzburg University Hospitals, Germany

Amethyst UK

Amethyst UK operates a specialist Intracranial Stereotactic Radiosurgery Service for the treatment of inoperable brain tumours in adults, on behalf of University College Hospital’s NHS Trust’s (UCLH) National Hospital for Neurology and Neurosciences; a world-renowned clinical research, teaching and tertiary service Centre of Excellence, named one of the top three leading Neurosciences Centres in the world by Newsweek.

Amethyst operates a paediatric brain tumour radiosurgery service in collaboration with Great Ormond Street Hospital for Children NHS Trust. Amethyst’s collaboration with ULCH is one of only two such national Centres of Excellence approved by NHS England; the other being the National Stereotactic Radiosurgery (SRS) Centre at the Royal Hallamshire Hospital, Sheffield where Amethyst is also a provider of SRS.